CRP and IL-6 are key indicators of systemic inflammation and have been linked to various chronic conditions, including cardiovascular disease and insulin resistance, both of which are commonly seen in individuals with T2DM [83]
Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
If low or low-normal, switch to high-dose b12 supplementation separate from multivitamin (1000 to 2000 mcg daily oral or regular injections)
It also makes a great add-on to your breakfast
Hannaert et al., 2002), while furosemide affects multiple K + Cl transporters and NKCCs (at higher concentrations) (Haas and McManus, 1983;Popowicz and Simmons, 1988;Hegde and Palfrey, 1992
No at-home test exists to measure this ratio
